Technology
Health
Biotechnology

Synthorx

$15.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.53 (3.50%) As of 2:34 PM EDT today
+$0.53 (3.50%) Today

Why Robinhood?

You can buy or sell Synthorx and other stocks, options, ETFs, and crypto commission-free!

About THOR

Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. Read More The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.

Employees
38
Headquarters
La Jolla, California
Founded
2014
Market Cap
476.67M
Price-Earnings Ratio
Dividend Yield
Average Volume
110.81K
High Today
$15.69
Low Today
$15.21
Open Price
$15.32
Volume
11.92K
52 Week High
$23.53
52 Week Low
$11.00

Collections

Technology
Health
Biotechnology
Cancer Prevention
2018 IPO
US
North America
Female CEOs

THOR Earnings

Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.